Background and Objective: Nowadays, the clinical
utility of carbapenems is threatened by the emergence of resistant bacteria, favored
by its increasing use. According to the WHO, Acinetobacter baumannii: nosocomial infection agent, tops the list of
priority antibiotic-resistant pathogens, considered to be the riskiest for humans.
This study sought to determine the prevalence of carbapenemase-producing Acinetobacter baumannii strains in four health
facilities in the Center and Littoral regions of Cameroon and the associated risk
factors. Materials and Method: An analytical cross-sectional study was conducted
over a six-month period from January to June 2022. All suspiciousA.baumanii isolates obtained from pathological samples at the bacteriology
laboratory of the different health facilities were systematically collected and
re-identified. Re-identification and antimicrobial susceptibility Testing (AST)？were performed using the VITEK 2 System and the Kirby-Bauer
method according to the guidelines of the Clinical and Laboratory Standards Institute
(CLSI). Detection and phenotypic characterization of carbapenemases was performed
according to adequate standard procedures. Results: A total of 168/226 clinical
isolates of Acinetobacter baumannii were
confirmed after re-identification, among which 52.69% derived from male patients,
55.09% from participants aged between 10-39 years old, and 46.71% from pus samples. A very high resistance rates to
all families of antibiotics was noted, except to colistin (10.2%). 40.12% of these
isolates produced carbapenemase, represented by 62.69% of class B and 37.31% of
class A.Carbapenemase production was observed only at HMR1,
References
[1]
Bouvet, P.J.M. and Grimont, P.A.D. (1986) Taxonomy of the Genus Acinetobacter with the Recognition of Acinetobacter baumannii sp. Nov., Acinetobacter haemolyticus sp. Nov., Acinetobacter johnsoniisp. Nov., and Acinetobacter junii sp. Nov. and Emended Descriptions of Acinetobacter calcoaceticus and Acinetobacter lwoffii. International Journal of Systematic and Evolutionary Microbiology, 36, 228-240. https://doi.org/10.1099/00207713-36-2-228
[2]
Lo, G., Dieng, A., Ba-Diallo, A., Samb, M., Tine, A., Lo Ndiaye, S.M., Farba, K., Diagne-Samb, H., Ngom-Cisse, S., Ndoye, A., Diop-Ndiaye, H., Toure-Kane, C., Gaye-Diallo, A., Mboup, S., Saad, C., Boye, B.C. and Camara, M. (2022) Molecular Epidemiology of Carbapenem-Resistant Acinetobacter baumannii Isolates in a Senegalese University Teaching Hospital. Journal of Advances in Microbiology, 22, 73-82. https://doi.org/10.9734/jamb/2022/v22i330449
[3]
Kindu, M., Derseh, L., Gelaw, B. and Moges, F. (2020) Carbapenemase-Producing Non-Glucose-Fermenting Gram-Negative Bacilli in Africa, Pseudomonas aeruginosa and Acinetobacter baumannii: A Systematic Review and Meta-Analysis. International Journal of Microbiology, 2020, Article ID: 9461901. https://doi.org/10.1155/2020/9461901
[4]
Hong, Y.K., Lee, J.Y., Wi, Y.M. and Ko, K.S. (2016) High Rate of Colistin Dependence in Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 71, 2346-2348. https://doi.org/10.1093/jac/dkw121
[5]
Raro, O.H.F., Gallo, S.W., Ferreira, C.A.S. and de Oliveira, S.D. (2017) Carbapenem-Resistant Acinetobacter baumannii Contamination in an Intensive Care Unit. Revista da Sociedade Brasileira de Medicina Tropical, 50, 167-172. https://doi.org/10.1590/0037-8682-0329-2016
[6]
WHO (2017) WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. WHO, Geneva. http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/
[7]
Hong, Y.-K., Kim, H. and Ko, K.S. (2020) Two Types of Colistin Heteroresistance in Acinetobacter baumannii Isolates. Emerging Microbes & Infections, 9, 2114-2123. https://doi.org/10.1080/22221751.2020.1821584
[8]
Nordmann, P. (2004) Carbapenemase-Producing Enterobacteriaceae: Overview of a Major Public Health Challenge. Médecine et Maladies Infectieuses, 44, 51-56. https://doi.org/10.1016/j.medmal.2013.11.007
[9]
Nordman, P., Naas, T. and Poirel, L. (2012) Global Spread of Carbapenemase- Producing Enterobacteriaceae. Emerging Infectious Diseases, 17, 1791-1798. https://doi.org/10.3201/eid1710.110655
[10]
Ayobami, O., Willrich, N., Harder, T., Okeke, I.N., Eckmanns, T. and Markwart, R. (2019) The Incidence and Prevalence of Hospital-Acquired (Carbapenem-Resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: A Systematic Review and Meta-Analysis. Emerging Microbes & Infections, 8, 1747-1759. https://doi.org/10.1080/22221751.2019.1698273
[11]
Benamrouche, N., Lafer, O., Benmahdi, L., Benslimani, A., Amhis, W., Ammari, H., Assaous, F., Azzam, A., Rahal, K. and Tali Maamar, H. (2020) Phenotypic and Genotypic Characterization of Multidrug-Resistant Acinetobacter baumannii Isolated in Algerian Hospitals, 2020. Journal of Infection in Developing Countries, 14, 1395-1401. https://doi.org/10.3855/jidc.12348
[12]
Ogbolu, D.O., Terry Alli, O.A., Oluremi, A.S., Temilola Ogunjimi, Y., et al. (2020) Contribution of NDM and OXA-Type Carbapenemases to Carbapenem Resistance in Clinical Acinetobacter baumannii from Nigeria. Infectious Diseases, 52, 644-650. https://doi.org/10.1080/23744235.2020.1775881
[13]
Eze1, E.C., El Zowalaty, M.E. and Pillay, M. (2021) Antibiotic Resistance and Biofilm Formation of Acinetobacter baumannii Isolated from High Risk Effluent Water in Tertiary Hospitals in South Africa. Journal of Global Antimicrobial Resistance, 27, 82-90. https://doi.org/10.1016/j.jgar.2021.08.004
[14]
CLSI (2017) Performance Standards for Antimicrobial Susceptibility Testing. Twentieth Informational Supplement, Document M100s-S27. Clinical and Laboratory Standards Institute, Wayne.
[15]
Giani, T., Tascini, C., Arena, F., Ciullo, I., Conte, V., Leonildi, A., et al. (2012) Rapid Detection of Intestinal Carriage of Klebsiella pneumoniae Producing KPC Carbapenemase during an Outbreak. Journal of Hospital Infection, 81, 119-122. https://doi.org/10.1016/j.jhin.2012.04.004
[16]
Franklin, C., Liolios, L. and Peleg, A.Y. (2006) Phenotypic Detection of Carbapenem-Susceptible Metallo-β-Lactamase-Producing Gram-Negative Bacilli in the Clinical Laboratory. Journal of Clinical Microbiology, 44, 3139-3144. https://doi.org/10.1128/JCM.00879-06
[17]
Rao, M.R., Urs, T.A., Chitharagi, V.B., et al. (2022) Rapid Identification of Carbapenemases by CarbAcineto NP Test and the Rate of Beta-Lactamases among Acinetobacter baumannii from a Teaching Hospital. Iranian Journal of Microbiology, 14, 174-180. https://doi.org/10.18502/ijm.v14i2.9184
[18]
Ebongue, C.O., Mengue, E.R., Nda Mefo’o, J.-P., Tsiazok, M.D., Kouassi, R.N. and Bum, E.N. (2015) Antimicrobial Multi-Resistance of Acinetobacter baumanii Isolated from Clinical Specimens in Douala (Cameroon). Journal of Diseases and Medicinal Plants, 1, 31-36. https://doi.org/10.11648/j.jdmp.20150102.12
[19]
Castilho, S.R.A., de Miranda Godoy, C.S., Guilarde, A.O., Cardoso, J.L., André, M.C.P., Junqueira-Kipnis, A.P. and Kipnis, A. (2017) Acinetobacter baumannii Strains Isolated from Patients in Intensive Care Units in Goiania, Brazil: Molecular and Drug Susceptibility Profiles. PLOS ONE, 12, e0176790. https://doi.org/10.1371/journal.pone.0176790
[20]
Venkataraman, R. and Yadav, U. (2022) Catheter-Associated Urinary Tract Infection: An Overview. Journal of Basic and Clinical Physiology and Pharmacology, 34, 5-10. https://doi.org/10.1515/jbcpp-2022-0152
[21]
Oikonomou, O., Sarrou, S., Papagiannitsis, C.C., et al. (2015) Rapid Dissemination of Colistin and Carbapenem Resistant Acinetobacter baumannii in Central Greece: Mechanisms of Resistance, Molecular Identification and Epidemiological Data. BMC Infectious Diseases, 15, Article No. 559. https://doi.org/10.1186/s12879-015-1297-x
[22]
Perovic, O. and Chetty, V. (2015) Antimicrobial Resistance Surveillance from Sentinel Public Hospitals, South Africa. Communicable Diseases Surveillance Bulletin, 14, 56-67.
[23]
Anane, Y.A., Apalata, T., Vasaikar, S., Okuthe, G.E. and Songca, S. (2020) Molecular Detection of Carbapenemase-Encoding Genes in Multidrug-Resistant Acinetobacter baumannii Clinical Isolates in South Africa. International Journal of Micro- biology, 2020, Article ID: 7380740. https://doi.org/10.1155/2020/7380740
[24]
Mohammed, M.A., Ahmed, M.T., Anwer, B.E., Aboshanab, K.M. and Aboulwafa, M.M. (2020) Propranolol, Chlorpromazine and Diclofenac Restore Susceptibility of Extensively Drug-Resistant (XDR)-Acinetobacter baumannii to Fluoroquinolones. PLOS ONE, 15, e0238195. https://doi.org/10.1371/journal.pone.0238195
[25]
Verma, P., Maurya, P., Tiwari, M. and Tiwari, V. (2019) In-Silico Interaction Studies Suggest RND Efflux Pump Mediates Polymyxin Resistance in Acinetobacter baumannii. Journal of Biomolecular Structure and Dynamics, 37, 95-103. https://doi.org/10.1080/07391102.2017.1418680
[26]
Asif, M., Alvi, I.A. and Rehman, S.U. (2018) Insight into Acinetobacter baumannii: Pathogenesis, Global Resistance, Mechanisms of Resistance, Treatment Options, and Alternative Modalities. Infection and Drug Resistance, 11, 1249-1260. https://doi.org/10.2147/IDR.S166750
[27]
Abd El-Baky, R.M., Farhan, S.M., Ibrahim, R.A., Mahran, K.M. and Hetta, H.F. (2020) Antimicrobial Resistance Pattern and Molecular Epidemiology of ESBL and MBL Producing Acinetobacter baumannii Isolated from Hospitals in Minia, Egypt. Alexandria Journal of Medicine, 56, 4-13. https://doi.org/10.1080/20905068.2019.1707350
[28]
Tunyapanit, W., Pruekprasert, P., Laoprasopwattana, K. and Chelae, S. (2014) Antimicrobial Susceptibility of Acinetobacter baumannii Isolated from Hospital Patients. ScienceAsia, 40, 28-34. https://doi.org/10.2306/scienceasia1513-1874.2014.40.028
[29]
van Duin, D. and Doi, Y. (2017) The Global Epidemiology of Carbapenemase- Producing Enterobacteriaceae. Virulence, 8, 460-469. https://doi.org/10.1080/21505594.2016.1222343
[30]
Dortet, L., Poirel, L. and Nordmann, P. (2014) Worldwide Dissemination of the NDM-Type Carbapenemases in Gram-Negative Bacteria. BioMed Research International, 2014, Article ID: 249856. https://doi.org/10.1155/2014/249856
[31]
Solgi, H., Badmasti, F., Giske, C.G., Aghamohammad, S. and Shahcheraghi, F. (2018) Molecular Epidemiology of NDM-1- and OXA-48-Producing Klebsiella pneumoniae in an Iranian Hospital: Clonal Dissemination of ST11 and ST893. Journal of Antimicrobial Chemotherapy, 73, 1517-1524. https://doi.org/10.1093/jac/dky081
[32]
Djuikoue, C.I., Djoulako, P.D.D., Wouambo, R.K., Tomi, C.N., Kiyang, C.P., Tchitchoua, M.C., Nyatchoutou, V.M., Messeu, B.K., Tagne, H.K., Nana, C.D.S., Benhamed, N., Kamga, H.G. and Thumamo Pokam, B.D. (2023) Phenotypic Characterization of Carbapenemase-Producing Enterobacteriaceae Strains in a Referral Teaching Hospital in Yaoundé, Cameroon. Open Journal of Medical Microbiology, 13, 52-67. https://doi.org/10.4236/ojmm.2023.131005
[33]
Djuikoue, C.I., Djouela Djoulako, P.D., Same Njanjo, H.V., Kiyang, C.P., Djantou Biankeu, F.L., Guegang, C., Tchouotou, A.S.D., Wouambo, R.K., Thumamo Pokam, B.D., Apalata, T. and Jeannot, K. (2023) Phenotypic Characterization and Prevalence of Carbapenemase-Producing Pseudomonas aeruginosa Isolates in Six Health Facilities in Cameroon. BioMed, 3, 77-88. https://doi.org/10.3390/biomed3010006
[34]
Djuikoue, C.I., Chounna, N.T., Djoulako, P.D.D., Wega, F., Nzenya, J.D., Nana, C.S., Ekeu, D.N., Messeu, B.K., Doumene, L.N., Talla, J.M., Fock, M. and Pokam, B.D.T. (2023) Risk Factors and Prevalence of Mother to New-Born Transmission of Carbapenemase Producing Enterobacteriaceae in Two Hospitals in Yaounde, Cameroon. Open Journal of Medical Microbiology, 13, 116-124. https://doi.org/10.4236/ojmm.2023.131010
[35]
Djuikoue, C.I., Djouela Djoulako, P.D., Wouambo, R.K., Lacmago, S.T., Dayomo, A., Kamga, H.G., Thumamo Pokam, B.D. and Apalata, T. (2022) Prevalence of Escherichia coli Producing Extended Spectrum Beta-Lactamase (ESBL) Driven Septicaemia in Children Aged 0 - 2 Years in Two Districts Hospitals in Yaounde, Cameroon. Bacteria, 1, 294-301. https://doi.org/10.3390/bacteria1040022
[36]
Djuikoue, C.I., Wega, F., Dayomo, A.L., Nana, C.D.S., Ekeu, D.N., Guegang, C.G., Djoulako, D.D., Mossanda, K.S., Nana, V.T. and Njajou, O. (2022) Freshwater Linked Resistance Profileand Prevalence of Escherichia Coli Producing ESBL Type CTX-M Strains in Cameroon Urban Cities. Frontiers in Environmental Microbiology, 8, 55-61.
[37]
McConnell, M.J., Actis, L. and Pachón, J. (2013) Acinetobacter baumannii: Human Infections, Factors Contributing to Pathogenesis and Animal Models. FEMS Microbiology Reviews, 37, 130-155. https://doi.org/10.1111/j.1574-6976.2012.00344.x
[38]
Lowe, M., Ehlers, M.M., Ismail, F., Peirano, G., Becker, P.J., Pitout, J.D.D., et al. (2018) Acinetobacter baumannii: Epidemiological and Beta-Lactamase Data from Two Tertiary Academic Hospitals in Tshwane, South Africa. Frontiers in Microbiology, 9, Article 1280. https://doi.org/10.3389/fmicb.2018.01280
